Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 17, 2011

ResearchDx to Offer CompanDx' Distiller Informatics Platform

  • ResearchDx will offer its customers the CompanDx Distiller bioinformatics platform for deriving biomarkers. The firms' partnership is designed to let clients initiate the development of companion diagnostic tests from the very earliest stages of drug development.

    "CompanDX' unique capabilities allow us to fully integrate bioinformatics into development of a diagnostic product from early in the discovery process,” states ResearchDx founders and principals Philip D. Cotter, Ph.D., and Mathew W. Moore, Ph.D.

    ResearchDx, which launched in February and calls itself as a contract diagnostics organization, offers clinical research services to design, produce, and validate diagnostic tests from initial assay conceptualization to regulatory approval.

    In March, CompanDx inked a multiyear agreement to use the CLIA-certified laboratory services of Clinical Reference Laboratory in the continued development of its Distiller technology, specifically in the development of the first "Time to Event" panel of breast cancer biomarkers, and companion diagnostics.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »